Search
Showing results for "lung disease preterm"
Staphylococcus aureus is a common cause of community and health care-associated bacteremia, with authors of recent studies estimating the incidence of S aureus bacteremia (SAB) in high-income countries between 8 and 26 per 100 000 children per year. Despite this, <300 children worldwide have ever been randomly assigned into clinical trials to assess the efficacy of treatment of SAB.
Children with ADHD are disadvantaged from an early age in key areas of learning, and this risk increased with reduction in gestational age at birth
A lifestyle intervention starting in the first-trimester pregnancy utilising e-health mode of delivery is feasible
The introduction of a formal medical team to Hospital in the Home (HiTH) demonstrated a positive clinical impact on Parenteral Antimicrobial Therapy (OPAT) patients' outcomes.
In Australia, there is little empirical research of the racial identity of Indigenous children and youth as the majority of the current literature focuses on...
ORIGINS has a large number of sub-projects exploring the link between a mother's diet during pregnancy and health outcomes of the child. Projects also explore nutrition and eating habits during the early years as well as general gut health
Desiree Dr Jackie Susan Lisa Zenobia Silva Davis Prescott Gibson Talati MBBS, FRACP, MPH, PhD BSc (Hons), PGradDipHlthProm, PhD MBBS BMedSci PhD
In 2006, when a Japanese scientist building on the earlier work of a British biologist discovered a way to reprogram adult cells into other cell types – making them ‘pluripotent’ – the scientific world was entranced.
To investigate the follow-up and outcomes of HIV-exposed infants in a setting of low HIV prevalence. This was a multicenter, retrospective study of live-born infants of women known to be living with HIV, at 9 tertiary pediatric centers in Australia and New Zealand from 2009-2025. Antenatal, perinatal, and postnatal data, and outcomes at clinic visits to 18 months of age were collected, including co-morbidities, development, and HIV results.
Convalscent plasma (CP) was identified as a potential therapy for COVID-19 available early in the pandemic.